4.7 Article

Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism

期刊

NEUROLOGY
卷 75, 期 15, 页码 1356-1361

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181f73649

关键词

-

资金

  1. High-Tech Research Center
  2. Japanese Ministry of Education, Culture, Sports, Science and Technology [21390272, 21591098, 22790829]
  3. Japanese Ministry of Health, Labour and Welfare [20261501, 22140501]
  4. Grants-in-Aid for Scientific Research [21591098, 22790829, 21390272] Funding Source: KAKEN

向作者/读者索取更多资源

Background: PLA2G6 is the causative gene for infantile neuroaxonal dystrophy, neurodegeneration associated with brain iron accumulation, and Karak syndrome. Based on previous reports, patients with PLA2G6 mutations could show axonal dystrophy, dystonia, dementia, and cerebellar signs. Recently, PLA2G6 was also reported as the causative gene for early-onset PARK14-linked dystonia-parkinsonism. Methods: To clarify the role of PLA2G6 mutation in parkinsonism, we conducted mutation analysis in 29 selected patients with very early-onset (<= 30, mean 21.2 +/- 8.4 years, +/-SD) parkinsonism. These patients had other clinical features (e. g., mental retardation/dementia [14/29], psychosis [15/29], dystonia [11/29], and hyperreflexia [11/29]). Results: Two novel compound heterozygous PLA2G6 mutations were detected (patient A: p.F72L/p.R635Q; patients B1 and B2: p.Q452X/p.R635Q). All 3 patients had early-onset L-dopa-responsive parkinsonism with dementia and frontotemporal lobar atrophy. Disease progression was relatively rapid. SPECT in patient B1 showed frontotemporal lobar hypoperfusion. MRI in patient A showed iron accumulation in the substantia nigra and striatum. Conclusions: Although the clinical presentation of PLA2G6-associated neurodegeneration was reported to be homogeneous, our findings suggest patients with PLA2G6 mutation could show heterogeneous phenotype such as dystonia-parkinsonism, dementia, frontotemporal atrophy/hypoperfusion, with or without brain iron accumulation. Based on the clinical heterogeneity, the functional roles of PLA2G6 and the roles of PLA2G6 variants including single heterozygous mutations should be further elucidated in patients with atypical parkinsonism, dementia, or Parkinson disease. PLA2G6 mutations should be considered in patients with early-onset L-dopa-responsive parkinsonism and dementia with frontotemporal lobar atrophy. Neurology (R) 2010;75:1356-1361

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据